IN8BIO, INC. — Director's Dealing 2023

Dec 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IN8BIO, INC. (INAB)
CIK: 0001740279
Period of Report: 2023-12-13

Reporting Person: Goswami Trishna (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-13	Common Stock	A	4098	—	Acquired	6729	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-13	Series A Warrants (right to buy)	$1.25	A	4098	Acquired	2025-06-13	Common Stock (4098)	Direct
2023-12-13	Series B Warrants (right to buy)	$1.50	A	4098	Acquired	2028-12-13	Common Stock (4098)	Direct

Footnotes

F1: The reported securities are included within 4,098 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 4,098 shares of common stock.

F2: Fully vested and exercisable.